A Phase 2 interventional study of dupilumab and Placebo in Allergic Bronchopulmonary Aspergillosis, sponsored by Regeneron Pharmaceuticals. Completed at 50 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States — none open to participants now, none under way, none of them phase 3. Aspergillosis, Allergic Bronchopulmonary · United States.
Among the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States, this one is the only one that started in 2020, is one of 3 in phase 2, and was the 8th registered.
42 studies on the registry are indexed under Aspergillosis, Allergic Bronchopulmonary; 13 are open to participants now.
Browse Aspergillosis, Allergic Bronchopulmonary studies →None of the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States is open now. The open studies under Aspergillosis, Allergic Bronchopulmonary, anywhere →
Of the 10 Aspergillosis, Allergic Bronchopulmonary studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is close to the median of 58 across 25 interventional studies indexed under Aspergillosis, Allergic Bronchopulmonary.
Median enrollment 35 across the 8 interventional studies, 52 across the 2 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 8 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 1 study filed under Aspergillosis, Allergic Bronchopulmonary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA).
The secondary objectives of the study are:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion / exclusion criteria applies.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)
Drug: dupilumab
Matching dupilumab without active substance
Drug: Placebo
Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
Also known as: • DUPIXENT, • REGN668, • SAR231893
Matching placebo
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo
Time frame: At Week 24
Annualized Rate of ABPA-related Exacerbations
Defined as severe respiratory exacerbations that are associated with a doubling of serum total Immunoglobulin E (IgE) from the prior pre-exacerbation value. Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)
Time frame: Over the 24 to 52 Week Treatment Period
Annualized Rate of Severe Respiratory Exacerbations
Defined as new onset of symptoms or clinical worsening of respiratory symptoms requiring systemic corticosteroid treatment for ≥3 consecutive days; for participants who are on maintenance systemic corticosteroids, at least double the dose of maintenance systemic corticosteroids for ≥3 consecutive days (with or without antibiotic therapy if indicated) Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)
Time frame: Over the 24 to 52 Week Treatment Period
Annualized Rate of Severe Respiratory Exacerbations Requiring Either Hospitalization or Observation for >24 Hours in an ED/Urgent Care Facility
Annualized rate of severe respiratory exacerbations requiring either hospitalization or observation for \>24 hours in an emergency department/urgent care facility (events per person-year) Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)
Time frame: Over the 24 to 52 Week Treatment Period
Change From Baseline in Asthma Control Questionnaire (ACQ)-5 Score
ACQ is completed by patient to measure both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment. The ACQ-5 score is the mean of the first 5 questions, between 0 (totally controlled) and 6 (severely uncontrolled). A higher score indicates lower asthma control. Participants with a score below 1.0 reflect adequately controlled asthma and participants with scores above 1.0 reflect inadequately controlled asthma. The optimal cut-point score of 1.50 should be used to be confident that a patient has inadequately controlled asthma.
Time frame: Over the 24 to 52 Week Treatment Period
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score
SGRQ will be completed by the patient to measure and quantify health status in adult participants with chronic airflow limitation. Total score ranges from 0 to 100. Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial). Lower score indicates better Quality of Life (QoL).
Time frame: Over the 24 to 52 Week Treatment Period
Percentage of Participants Achieving a Reduction in the SGRQ Total Score of 4 Points or Greater From Baseline
SGRQ will be completed by the patient to measure and quantify health status in adult participants with chronic airflow limitation. Total score ranges from 0 to 100. Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial). Lower score indicates better Quality of Life (QoL).
Time frame: Up to 52 Weeks
Percent Change From Baseline in Total IgE in Serum
Time frame: Over the 24 to 52 Week Treatment Period
Percent Change From Baseline in A Fumigatus-specific IgE in Serum
Time frame: Over the 24 to 52 Week Treatment Period
Absolute Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)
Time frame: Over the 24 to 52 Week Treatment Period
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)
Time frame: Over the 24 to 52 Week Treatment Period
Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Baseline
Time frame: Through the end of the 52 Week Treatment Period
Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Responses and Titer Over Time
Time frame: Up to 64 Weeks
Concentrations of Functional Dupilumab in Serum by Treatment Regimen
Time frame: Up to 64 Weeks
| Milestone | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Started | 27 | 35 |
| Completed | 20 | 29 |
| Not completed | 7 | 6 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Decision by the investigator/sponsor | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Travel limitations | 1 | 1 |
| Liters | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo | 0.002 ± 0.0558 | 0.203 ± 0.0482 |
Defined as severe respiratory exacerbations that are associated with a doubling of serum total Immunoglobulin E (IgE) from the prior pre-exacerbation value. Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)
| Events per person-year | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Adjusted Rate | NA (NA to NA) | NA (NA to NA) |
| Unadjusted Rate | 0 (0 to 0) | 0 (0 to 0) |
Defined as new onset of symptoms or clinical worsening of respiratory symptoms requiring systemic corticosteroid treatment for ≥3 consecutive days; for participants who are on maintenance systemic corticosteroids, at least double the dose of maintenance systemic corticosteroids for ≥3 consecutive days (with or without antibiotic therapy if indicated) Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)
| Events per person year | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Adjusted Rate | 1.551 | 0.695 |
| Unadjusted Rate | 0.943 | 0.545 |
Annualized rate of severe respiratory exacerbations requiring either hospitalization or observation for \>24 hours in an emergency department/urgent care facility (events per person-year) Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)
| Events per person year | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Adjusted Rate | NA | NA |
| Unadjusted Rate | 0.041 | 0.128 |
ACQ is completed by patient to measure both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment. The ACQ-5 score is the mean of the first 5 questions, between 0 (totally controlled) and 6 (severely uncontrolled). A higher score indicates lower asthma control. Participants with a score below 1.0 reflect adequately controlled asthma and participants with scores above 1.0 reflect inadequately controlled asthma. The optimal cut-point score of 1.50 should be used to be confident that a patient has inadequately controlled asthma.
| ACQ-5 Score | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 24 | -1.10 ± 1.102 | -1.24 ± 1.081 |
| Week 36 | -0.81 ± 0.878 | -1.15 ± 1.208 |
| Week 44 | -0.87 ± 1.233 | -1.01 ± 1.359 |
| Week 52 | -0.84 ± 1.183 | -1.29 ± 1.241 |
SGRQ will be completed by the patient to measure and quantify health status in adult participants with chronic airflow limitation. Total score ranges from 0 to 100. Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial). Lower score indicates better Quality of Life (QoL).
| SGRQ Total Score | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 12 | -9.463 ± 16.3993 | -17.956 ± 14.6184 |
| Week 24 | -7.626 ± 14.5412 | -23.079 ± 15.9104 |
| Week 36 | -8.796 ± 16.4257 | -20.178 ± 15.5266 |
| Week 52 | -8.938 ± 15.3127 | -25.309 ± 20.1035 |
SGRQ will be completed by the patient to measure and quantify health status in adult participants with chronic airflow limitation. Total score ranges from 0 to 100. Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial). Lower score indicates better Quality of Life (QoL).
| Percent | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 12 | 50.0 (30.72 to 69.28) | 85.3 (69.87 to 93.55) |
| Week 24 | 63.6 (42.95 to 80.27) | 87.1 (71.15 to 94.87) |
| Week 36 | 57.1 (36.55 to 75.53) | 86.2 (69.44 to 94.50) |
| Week 52 | 68.4 (46.01 to 84.64) | 89.3 (72.80 to 96.29) |
| Percent | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 24 | -0.665 ± 40.2236 | -47.245 ± 19.4110 |
| Week 36 | -5.945 ± 27.6767 | -57.752 ± 18.0812 |
| Week 52 | -2.767 ± 42.8914 | -62.175 ± 17.0285 |
| Percent | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 24 | 0.099 ± 39.7612 | -39.859 ± 25.3095 |
| Week 36 | 6.766 ± 39.9041 | -45.654 ± 26.7915 |
| Week 52 | 12.618 ± 94.6306 | -49.126 ± 30.6790 |
| ppb | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 24 | -4.80 ± 23.521 | -22.04 ± 38.410 |
| Week 36 | 3.11 ± 20.571 | -21.48 ± 40.538 |
| Week 44 | 1.38 ± 21.896 | -19.18 ± 37.122 |
| Week 52 | -4.79 ± 27.634 | -19.04 ± 35.471 |
| Percent | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 24 | 1.67 ± 44.069 | -29.91 ± 32.527 |
| Week 36 | 19.80 ± 44.053 | -24.56 ± 43.975 |
| Week 44 | 15.43 ± 54.887 | -19.83 ± 48.308 |
| Week 52 | 2.55 ± 56.506 | -20.35 ± 48.100 |
| Participants with TEAEs | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Baseline | 22 | 30 |
| Participants | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| TE & TB Maximum Titer Category Low (<1,000) | 0 | 1 |
| TE & TB Maximum Titer Category Moderate (1,000 to 10,000) | 0 | 0 |
| TE & TB Maximum Titer Category High (>10,000) | 0 | 0 |
| mg/L | Dupilumab 300 mg Q2W |
|---|---|
| Week 0 | 0 ± 0 |
| Week 12 | 63.8 ± 35.4 |
| Week 24 | 86.5 ± 53.6 |
| Week 52 | 82.2 ± 55.4 |
| Week 64 | 1.67 ± 4.38 |
Collected over From Day 1 to EOS (End Of Study) visit ~(up to 64 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/27 (3.7%) | 5/27 (18.5%) | 19/27 (70.4%) |
| Dupilumab 300 mg Q2W | 1/35 (2.9%) | 3/35 (8.6%) | 29/35 (82.9%) |
| Event | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| InfluenzaInfections and infestations | 0/27 | 2/35 |
| Pneumonia bacterialInfections and infestations | 0/27 | 2/35 |
| Bronchopulmonary aspergillosis allergicInfections and infestations | 1/27 | 0/35 |
| Lower respiratory tract infectionInfections and infestations | 1/27 | 0/35 |
| PneumoniaInfections and infestations | 1/27 | 0/35 |
| Trisomy 16Congenital, familial and genetic disorders | 1/27 | 0/35 |
| Pelvic fractureInjury, poisoning and procedural complications | 1/27 | 0/35 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/27 | 0/35 |
| Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/27 | 0/35 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/27 | 0/35 |
| Event | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 9/27 | 4/35 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/27 | 8/35 |
| COVID-19Infections and infestations | 3/27 | 6/35 |
| HeadacheNervous system disorders | 2/27 | 6/35 |
| Upper respiratory tract infectionInfections and infestations | 1/27 | 4/35 |
| Urinary tract infectionInfections and infestations | 0/27 | 4/35 |
| Injection site erythemaGeneral disorders | 0/27 | 4/35 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 3/27 | 4/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/27 | 4/35 |
| Respiratory tract infection bacterialInfections and infestations | 3/27 | 0/35 |
| Age, Customized(years) | Placebo | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| Mean | 57.1 ± 14.38 | 61.2 ± 8.62 | 59.4 ± 11.56 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| Female | 17 | 22 | 39 |
| Male | 10 | 13 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 6 |
| Not Hispanic or Latino | 24 | 29 | 53 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Placebo | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| White | 25 | 28 | 53 |
| Asian | 1 | 4 | 5 |
| Other | 0 | 1 | 1 |
| Not Reported | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Sep 2020 to primary completion in Jul 2023, 34 months.
Results were first posted in Aug 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab
Aspergillosis, Allergic Bronchopulmonary →